NO20050300L - Stabiliserte formuleringer av alfa-adrenergisk reseptor-antagonister og anvendelse derav - Google Patents

Stabiliserte formuleringer av alfa-adrenergisk reseptor-antagonister og anvendelse derav

Info

Publication number
NO20050300L
NO20050300L NO20050300A NO20050300A NO20050300L NO 20050300 L NO20050300 L NO 20050300L NO 20050300 A NO20050300 A NO 20050300A NO 20050300 A NO20050300 A NO 20050300A NO 20050300 L NO20050300 L NO 20050300L
Authority
NO
Norway
Prior art keywords
adrenergic receptor
receptor antagonists
alpha
stabilized formulations
stable liquid
Prior art date
Application number
NO20050300A
Other languages
English (en)
Inventor
Eckard Weber
Andrew Xian Chen
Julius Knowles
Original Assignee
Novalar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novalar Pharmaceuticals Inc filed Critical Novalar Pharmaceuticals Inc
Publication of NO20050300L publication Critical patent/NO20050300L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det beskrives preparater og stabile, flytende formuleringer inneholdende ( adrenergiske reseptor antagonister og deres anvendelse for å øke blodstrømmen. I en utførelsesform er den stabile, flytende formuleringen brukbar for å reversere virkningene av et anestetikum, fortrinnsvis et lengevarende lokalt anestetikum som er administrert i forbindelse med en ( adrenergisk reseptor agonist.
NO20050300A 2002-06-20 2005-01-19 Stabiliserte formuleringer av alfa-adrenergisk reseptor-antagonister og anvendelse derav NO20050300L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38620302P 2002-06-20 2002-06-20
US41104902P 2002-09-17 2002-09-17
US42115202P 2002-10-24 2002-10-24
US47392003P 2003-05-29 2003-05-29
PCT/US2003/019440 WO2004000219A2 (en) 2002-06-20 2003-06-20 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof

Publications (1)

Publication Number Publication Date
NO20050300L true NO20050300L (no) 2005-03-04

Family

ID=30003979

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050300A NO20050300L (no) 2002-06-20 2005-01-19 Stabiliserte formuleringer av alfa-adrenergisk reseptor-antagonister og anvendelse derav

Country Status (10)

Country Link
EP (1) EP1539170B1 (no)
JP (2) JP4787977B2 (no)
AU (1) AU2003247568B2 (no)
BR (2) BR0311965A (no)
CA (1) CA2489526C (no)
HK (1) HK1079444A1 (no)
IL (1) IL165599A (no)
MX (1) MXPA04012507A (no)
NO (1) NO20050300L (no)
WO (1) WO2004000219A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2888699A1 (fr) 2005-07-13 2007-01-19 France Telecom Dispositif de codage/decodage hierachique
FR2897742A1 (fr) 2006-02-17 2007-08-24 France Telecom Codage/decodage perfectionnes de signaux numeriques, en particulier en quantification vectorielle avec codes a permutation
NL2004260C2 (en) * 2010-02-18 2011-08-22 Univ Amsterdam Disinfectant composition and its use in dental treatment.
WO2014121027A1 (en) * 2013-02-01 2014-08-07 Oculars Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
WO2014121028A1 (en) * 2013-02-01 2014-08-07 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
UY35988A (es) 2014-02-27 2015-09-30 Sint Sa Proceso para la producción de una solución inyectable de noradrenalina de baja concentración
WO2018140894A1 (en) 2017-01-30 2018-08-02 Nevakar, Inc Norepinephrine compositions and methods therefor
US20200261422A1 (en) * 2019-02-15 2020-08-20 Massachusetts Institute Of Technology Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents
US12097170B2 (en) 2020-03-06 2024-09-24 Baxter International Inc. Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation
CN115368310A (zh) * 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659714A (en) * 1984-03-27 1987-04-21 Dentsply, Ltd. Anesthetic methods for mammals
US4938970A (en) 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US6387052B1 (en) 1991-01-29 2002-05-14 Edwards Lifesciences Corporation Thermodilution catheter having a safe, flexible heating element
EP0691124A1 (en) 1994-07-07 1996-01-10 Sara Lee/DE N.V. Mouth care products
US6331291B1 (en) 1996-05-30 2001-12-18 William R. Glace Dentifrice gel/paste compositions
US5908612A (en) 1996-12-31 1999-06-01 Basf Corporation Oral care compositions comprising liquid polyoxyalkylene compounds as solubilizers/gelling agents
FR2768620B1 (fr) 1997-09-22 2000-05-05 Rhodia Chimie Sa Formulation buccodentaire comprenant des nanofibrilles de cellulose essentiellement amorphes
AU6448498A (en) 1998-03-06 1999-09-20 Fmc Corporation High moisture toothpaste
US6187293B1 (en) 1998-04-27 2001-02-13 Fmc Corporation Process for making toothpaste using low levels of carrageenan
US6482426B1 (en) * 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
CA2408417C (en) * 2000-05-12 2009-09-15 Novalar Pharmaceuticals, Inc. Local anesthetic methods and kits

Also Published As

Publication number Publication date
JP2005533869A (ja) 2005-11-10
JP2010280702A (ja) 2010-12-16
AU2003247568B2 (en) 2008-03-06
IL165599A (en) 2015-01-29
JP4787977B2 (ja) 2011-10-05
BR0311965A (pt) 2005-03-29
AU2003247568A1 (en) 2004-01-06
IL165599A0 (en) 2006-01-15
CA2489526A1 (en) 2003-12-31
CA2489526C (en) 2012-03-20
EP1539170B1 (en) 2014-08-13
WO2004000219A3 (en) 2004-03-11
MXPA04012507A (es) 2005-06-08
EP1539170A4 (en) 2011-01-05
EP1539170A2 (en) 2005-06-15
WO2004000219A2 (en) 2003-12-31
HK1079444A1 (en) 2006-04-07
BRPI0311965B1 (pt) 2018-04-24

Similar Documents

Publication Publication Date Title
NO20050300L (no) Stabiliserte formuleringer av alfa-adrenergisk reseptor-antagonister og anvendelse derav
DK1280531T3 (da) Formulering bestående af phentolaminmesylat og anvendelse heraf
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
ECSP045410A (es) Nuevos derivados de piridazin-3(2h)-ona
RS50814B (sr) Tartaratne soli 5,8,14-triazatetraciklo(10.3.1.02,11.04,9)- heksadeka-2(11),3,5,7,9-pentaena
CL2009001278A1 (es) Compuestos biciclicos, derivados de 1-(4-pipridinil)-1,3-dihidro-2h-indol-2-ona sustituidos, analogos de nociceptina; composicion farmaceutica; y su uso en el tratamiento del dolor (div. sol. 2103-03)
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
DE60328974D1 (de) (+)-2-ä1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylü-4-acetylaminoisoindolin-1,3-dion zur verwendung in der behandlung von psoriasis durch orale verabreichung
SV2005002148A (es) "compuestos moduladores de la actividad c-kit y usos de los mismos"
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
CL2004000788A1 (es) Compuestos derivados de n-[2-oxo-6-(aril o heteroaril)azepan-3-il]-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxamida, antagonistas de los receptores cgrp; composicion farmaceutica; y uso del compuesto en el tratamiento del d
ECSP045519A (es) Nuevos derivados de quinuclidina-amida
AR021055A1 (es) Derivados de pirazolopiridina
SE0402762D0 (sv) Indazole sulphonamide derivatives
BR0016275A (pt) Combinações farmacêuticas e seu uso no tratamento de distúrbios gastrointestinais
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
NO20051023L (no) Oral administrering av calcitonin
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
NO20022525D0 (no) Farmasöytiske formuleringer inneholdende zolmitriptan
ID25789A (id) KOMBINASI DARI INHIBITOR MONOAMINA OKSIDASI DAN ANTAGONIS ATAU SEBAGIAN AGONIS h5-HT1B
NO20004931L (no) Anvendelse av dexmedetomidin til sedering pÕ intensivavdeling
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application